Compare EFR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFR | MIRM |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.9M | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | EFR | MIRM |
|---|---|---|
| Price | $11.09 | $102.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $102.64 |
| AVG Volume (30 Days) | 88.6K | ★ 733.6K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 9.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | N/A | ★ $471,794,000.00 |
| Revenue This Year | N/A | $55.91 |
| Revenue Next Year | N/A | $23.97 |
| P/E Ratio | $7.74 | ★ N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $10.95 | $36.88 |
| 52 Week High | $13.29 | $105.74 |
| Indicator | EFR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 41.65 | 65.62 |
| Support Level | $10.95 | $98.70 |
| Resistance Level | $11.16 | $105.74 |
| Average True Range (ATR) | 0.08 | 3.49 |
| MACD | -0.01 | -0.80 |
| Stochastic Oscillator | 36.47 | 67.40 |
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.